Tyson Foods to close major Nebraska beef plant amid cattle shortage - WSJ
Investing.com -- Bioaffinity Technologies Inc (NASDAQ:BIAF) stock soared 79% in premarket trading Friday after the biotechnology company released three new case studies highlighting the effectiveness of its CyPath Lung test in detecting early-stage lung cancer and helping physicians avoid unnecessary invasive procedures.
The company reported that in one case, the CyPath Lung test led to the detection of Stage 1A lung cancer, its earliest and potentially curable stage. In two other cases, the test helped patients avoid risky invasive procedures by providing clearer diagnostic information.
"These three new cases, provided by a Texas pulmonologist who has been using CyPath Lung for more than a year, reflect what we’re hearing from many physicians – CyPath Lung enhances clinical decision-making by personalizing care and playing a critical role in refining the diagnostic pathway," said Dr. Gordon Downie, Chief Medical Officer of bioAffinity Technologies .
The case studies included a 68-year-old smoker whose positive CyPath Lung result prompted him to proceed with a biopsy that confirmed Stage 1A lung cancer. In another case, a negative CyPath Lung result helped a patient avoid an unnecessary biopsy for a suspicious nodule, allowing for monitoring instead. The third case involved a patient with end-stage COPD and previous lung cancer who received radiation therapy based on a positive CyPath Lung result when a biopsy posed significant risks.
The company’s technology aims to address the challenges in diagnosing indeterminate pulmonary nodules found during imaging, potentially reducing unnecessary procedures while enabling earlier cancer detection.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.